LAG-3 protein Archives

FDA approves BMS’ first-in-class LAG-3-blocking antibody combination for advanced melanoma

Approvals, Bristol Myers Squibb, Checkpoint Inhibitors, Clinical Trial Endpoints, Clinical Trials, FDA, First-In-Class, LAG-3 protein, Metastatic Melanoma, PD-1/PD-L1 inhibitors, Primary Endpoints, Progression-Free Survival (PFS), R&D

Bristol Myers Squibb’s Opdualag – a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion – was approved by the U.S. Food and Drug Administration for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

March 18, 2022/by Andrew Humphreys

New Bristol Myers immunotherapy combo better than Opdivo alone in melanoma study

Blockbusters, Bristol Myers Squibb, Checkpoint Inhibitors, Clinical Trials, Combination Therapies, Immuno-oncology, Immunotherapies, LAG-3 protein, Melanoma, Progression-Free Survival (PFS), R&D, T-Cells, Therapeutics

An experimental Bristol Myers Squibb drug from a new class of immunotherapy used in combination with the company’s big-selling cancer medicine Opdivo significantly extended the time it took for advanced melanoma to worsen compared with Opdivo alone, according to early data from a study released on May 19.

May 19, 2021/by Andrew Humphreys